ReviewHealth science reports2025
Association Between GLP1 RAs Use and Risk of Colorectal Cancer: A Systematic Review and Meta-Analysis.
Review in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Weight Loss, Obesity Medication, and Risk of Obesity-Associated Cancer: A Meta-Analysis of Randomized Controlled Trials.Obesity (Silver Spring, Md.) · 2026Pooled it
- Shaping the future of early-onset colorectal cancer prevention.Nature reviews. Cancer · 2026Review
- Role of GLP-1 receptor agonists in the prevention and treatment of obesity-related cancer.Internal and emergency medicine · 2026Review
- The association between genetically proxied GLP-1 receptor agonists and cancer risks.Annals of medicine and surgery (2012) · 2026Article
- Glucagon-like peptide 1 receptor agonists and cancer risk: the good, the bad and the unknown.Nature reviews. Clinical oncology · 2026Review
- Association of dual SGLT-2 inhibitor and GLP-1 receptor agonist therapy with colon cancer risk in post-polypectomy patients with diabetes: a target trial emulation.Diabetology & metabolic syndrome · 2026Article
- The different colorectal tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 68 randomized controlled trials.International journal of surgery (London, England) · 2026Article
- Pharmacological mechanisms and clinical impacts of antidiabetic drugs on colorectal cancer risk: a systematic review.Frontiers in pharmacology · 2026Review
- GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research.The Journal of clinical investigation · 2025Review
- Glucagon-like Peptide-1 Receptor Agonists and Colorectal Cancer Risk.AACE endocrinology and diabetesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: As the global prevalence of type 2 diabetes mellitus (T2DM) continues to rise, addressing its associated health risks, including colorectal cancer (CRC), is important. This study examines the relationship between the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and the risk of CRC in comparison with other antidiabetic therapies. Methods: We conducted a systematic search of PubMed, Embase, and Web of Science up to August 10, 2024, following PRISMA guidelines. Data extraction and screening were performed using Nested Knowledge software. Meta-analysis random effect model pooled Risk ratios (RRs) calculated using was performed using R v4.4 statistical software g. The protocol was registered with PROSPERO. Results: Out of 1825 identified studies, five met the inclusion criteria, involving 2,047,256 T2DM patients assessing CRC risk. GLP-1RAs were associated with a significant reduction in CRC risk compared to thiazolidinediones (RR: 0.82, 95% CI: 0.68-0.96), insulin (RR: 0.57, 95% CI: 0.32-0.81), and SGLT2 inhibitors (RR: 0.77, 95% CI: 0.59-0.95). Comparisons with sulfonylureas, DPP-4 inhibitors, and metformin were not statistically significant. A potential protective effect against alpha-glucosidase inhibitors was observed (RR: 0.59, 95% CI: 0.18-1.00) but requires further investigation. Conclusion: The use of GLP-1RAs in T2DM is linked to a reduced risk of CRC compared to several standard antidiabetic therapies. These findings underscore the importance of considering long-term cancer risks in diabetes management and highlight the need for continued research to fully understand the implications of GLP-1RA use in T2DM patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.